You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR2 gene rearrangement

Showing 1 - 25 of 6,091
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

Not yet recruiting
  • Advanced Cholangiocarcinoma
  • +2 more
  • (no location specified)
Feb 3, 2023

Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)

Recruiting
  • Solid Tumor
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

Cholangiocarcinoma Trial in Shanghai (Pemigatinib)

Active, not recruiting
  • Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Zhongshan Hospital Affiliated to Fudan University
Oct 3, 2022

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma Trial in Worldwide (derazantinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular and Cholangiocarcinoma
  • Phoenix, Arizona
  • +40 more
Mar 7, 2022

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Rearrangements
  • Albuquerque, New Mexico
  • +100 more
Feb 1, 2023

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation
  • Gilbert, Arizona
  • +115 more
Oct 17, 2022

MPN (Myeloproliferative Tumors) Trial in Worldwide (Pemigatinib)

Active, not recruiting
  • MPN (Myeloproliferative Neoplasms)
  • Phoenix, Arizona
  • +32 more
Jun 24, 2022

Cholangiocarcinoma,Adult Trial (3D185)

Not yet recruiting
  • Cholangiocarcinoma,Adult
  • (no location specified)
Sep 2, 2021

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Urothelial Carcinoma Trial in Shanghai (AZD4547)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Oct 20, 2021

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

Recruiting
  • Nsclc
  • +5 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 25, 2021

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

Recruiting
  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • +2 more
  • Futibatinib and Binimetinib
  • Santa Monica, California
  • +2 more
Jun 2, 2022

Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia Trial in Kansas City, Cincinnati

Recruiting
  • Relapsed/Refractory Leukemias
  • +4 more
  • Kansas City, Missouri
  • +1 more
Jul 18, 2022

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022